mTORC1 and ferroptosis: Regulatory mechanisms and therapeutic potential
-
- Guang Lei
- Department of Radiation Oncology Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University Changsha Hunan China
-
- Li Zhuang
- Department of Experimental Radiation Oncology The University of Texas MD Anderson Cancer Center Houston Texas USA
-
- Boyi Gan
- Department of Experimental Radiation Oncology The University of Texas MD Anderson Cancer Center Houston Texas USA
説明
<jats:title>Abstract</jats:title><jats:p>Ferroptosis, a form of regulated cell death triggered by lipid hydroperoxide accumulation, has an important role in a variety of diseases and pathological conditions, such as cancer. Targeting ferroptosis is emerging as a promising means of therapeutic intervention in cancer treatment. Polyunsaturated fatty acids, reactive oxygen species, and labile iron constitute the major underlying triggers for ferroptosis. Other regulators of ferroptosis have also been discovered recently, among them the <jats:styled-content>m</jats:styled-content>echanistic <jats:styled-content>t</jats:styled-content>arget of <jats:styled-content>r</jats:styled-content>apamycin <jats:styled-content>c</jats:styled-content>omplex <jats:styled-content>1</jats:styled-content> (mTORC1), a central controller of cell growth and metabolism. Inhibitors of mTORC1 have been used in treating diverse diseases, including cancer. In this review, we discuss recent findings linking mTORC1 to ferroptosis, dissect mechanisms underlying the establishment of mTORC1 as a key ferroptosis modulator, and highlight the potential of co‐targeting mTORC1 and ferroptosis in cancer treatment. This review will provide valuable insights for future investigations of ferroptosis and mTORC1 in fundamental biology and cancer therapy.</jats:p>
収録刊行物
-
- BioEssays
-
BioEssays 43 (8), 2100093-, 2021-06-14
Wiley
